Hillsdale Investment Management Inc. Has $562,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

Hillsdale Investment Management Inc. reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,800 shares of the medical equipment provider’s stock after selling 1,200 shares during the period. Hillsdale Investment Management Inc.’s holdings in Hologic were worth $562,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. General Partner Inc. acquired a new stake in Hologic during the fourth quarter worth approximately $26,000. Groupama Asset Managment increased its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the period. First Horizon Advisors Inc. boosted its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the period. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on HOLX shares. Raymond James reiterated an “outperform” rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Citigroup reduced their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research note on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Stock Up 0.7 %

Hologic stock opened at $61.89 on Tuesday. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm’s 50-day simple moving average is $65.89 and its 200 day simple moving average is $73.81. The stock has a market cap of $13.89 billion, a PE ratio of 19.52, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.